Elinogrel (PRT060128) potassium functions as a reversible, competitive, and orally active antagonist of the P2Y12 receptor. This compound effectively inhibits thrombosis .

Elinogrel, administered orally at 60 mg/kg daily for three days, has been shown to inhibit thrombosis [2]. At a dose of 1 mg/kg intravenously, Elinogrel can prevent residual thrombosis in mice treated with clopidogrel at 50 mg/kg orally for three days in a FeCl3-induced vascular injury model [2]. Animal Model: C57BL/6J mice [2] Dosage: 60 mg/kg Administration: P.o.; daily for 3 days Result: Inhibited thrombosis in mouse.